Medsafe aware of weight-loss drug concerns

New Zealand medicines regulator Medsafe says it is aware of international concerns about weight-loss drug Reductil and is reviewing the risks.

Group manager Stewart Jessamine said Medsafe would take into account study data referred to the United States Food and Drug Administration (FDA) which suggests those taking Reductil (sibutramine) could be at increased risk of heart problems.

It was now waiting on more information from the drug's US manufacturer, including the study data, before taking any further action.

"Medsafe will provide further advice to healthcare professionals and consumers as necessary," Dr Jessamine said.

"In the meantime, health care professionals are reminded to avoid using sibutramine in patients with a history of coronary artery disease, congestive heart failure, tachycardia, peripheral arterial occlusive disease, arrhythmia, or stroke, as recommended in the sibutramine data sheet."

He urged patients to report any suspected adverse reactions to their doctor.

- NZPA